Skip to main content

Table 1 Baseline demographics (ITT population)

From: Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol

 

Alirocumab (n = 128)

Usual carea (n = 58)

Age, years, mean (SD)

62.1 (9.5)

63.4 (9.0)

Male, n (%)

65 (50.8)

28 (48.3)

Race, n (%)

 American Indian or Alaska Native

3 (2.3)

0

 Asian/Oriental

2 (1.6)

6 (10.3)

 Black

4 (3.1)

2 (3.4)

 Other

3 (2.3)

0

 White/Caucasian

116 (90.6)

50 (86.2)

Ethnicity, n (%)

 Hispanic or Latino

17 (13.3)

8 (13.8)

 Not Hispanic or Latino

110 (85.9)

50 (86.2)

 Not reported/unknown

1 (0.8)

0

Weight, kg, mean (SD)

93.6 (19.7)

93.8 (16.4)

BMI, kg/m2, mean (SD)

32.6 (4.9)

33.0 (4.6)

Systolic blood pressure, mmHg, mean (SD)

130.0 (14.4)

134.9 (15.7)

Diastolic blood pressure, mmHg, mean (SD)

76.3 (9.8)

77.2 (9.2)

ASCVD (CHD, ischemic stroke, PAD), n (%)

47 (36.7)

24 (41.4)

HbA1c, %, mean (SD)

7.0 (0.9)

7.3 (0.8)

Fasting plasma glucose, mg/dL, mean (SD)

150.2 (39.2)

153.2 (41.1)

Individuals receiving insulin at baseline, n (%)

52 (40.6)

26 (44.8)

Baseline lipids, mean (SD)

 Non-HDL-C, mg/dL

170.3 (48.2)

166.3 (48.8)

  mmol/L

4.41 (1.25)

4.31 (1.26)

 LDL-C (beta-quantification), mg/dL

112.8 (43.7)

110.7 (42.1)

  mmol/L

2.92 (1.13)

2.87 (1.09)

 ApoB, mg/dL

109.3 (27.4)

108.1 (28.9)

 LDL particle number, nmol/L

1497.3 (532.0)

1491.5 (545.1)

 Lipoprotein(a), mg/dL, median (Q1:Q3)

18.0 (5.0:55.0)

9.5 (4.0:30.0)

 TGs, mg/dL, median (Q1:Q3)

281.5 (245.0:369.0)

269.0 (232.0:328.0)

  mmol/L

3.19 (2.77:4.17)

3.04 (2.62:3.71)

 HDL-C, mg/dL

34.4 (6.2)

34.3 (5.9)

  mmol/L

0.89 (0.16)

0.89 (0.15)

  1. ASCVD atherosclerotic cardiovascular disease, ApoB apolipoprotein B, BMI body mass index, CHD coronary heart disease, HbA1c glycated hemoglobin, HDL-C high-density lipoprotein cholesterol, ITT intention-to-treat, LDL low-density lipoprotein, LDL-C low-density lipoprotein cholesterol, PAD peripheral artery disease, SD standard deviation, TG triglyceride
  2. aOptions included ezetimibe, fenofibrate, no additional lipid-lowering therapy, omega-3 fatty acid, and nicotinic acid